Affiliation:
1. The National Hospital for Neurology and Neurosurgery; Chalfont Centre for Epilepsy, United Kingdom
2. The National Hospital for Neurology and Neurosurgery
Abstract
Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed whether the risk is increased in patients receiving concomitant valproate therapy in a population of 103 adult patients with intractable epilepsy, who had lamotrigine added to their treatment. Of the 33 patients taking valproate, 10 (30%) developed a rash, whilst of the 70 not taking valproate, only 6 (8%) developed a rash. This suggests a significantly higher risk of cutaneous rash when starting lamotrigine in patients already taking valproate (p<0.02).
Subject
Neurology,Clinical Neurology
Reference5 articles.
1. Human safety of lamotrigine;Betts T;Epilepsia,1991
2. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy;Sander JWAS;Epilep Res,1990
3. Recent advances in epilepsy;Pedley TA,1992
4. The safety and tolerability of lamotrigine;Srinivasan J;Rev Contemp Pharmacother,1994
5. Sodium valproate acutely inhibits lamotrigine metabolism;Yuen AWC;Br J Clin Pharmacol,1992
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献